Abstract
Cancer predisposition genes (CPGs) describe genes in which germline mutations result in increased risk of cancer. Over 100 CPGs have already been discovered and transformative advances in DNA analysis are leading to many new CPG discoveries. These fast, affordable methods for analysing the DNA sequence can also be utilised in diagnostics to increase substantially clinical testing of CPGs. In turn, this has potential to provide substantial cost-effective health benefits with respect to cancer treatment in people with the disease and cancer prevention in healthy individuals. In this review, I outline the clinical benefits of testing for CPGs and how increased testing can be achieved.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
